Financial Performance - The company's revenue for Q1 2025 reached ¥135,213,242.04, representing a 48.21% increase compared to ¥91,229,728.71 in the same period last year[5]. - Net profit attributable to shareholders was ¥34,798,977.44, up 16.66% from ¥29,828,839.74 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥28,015,509.20, reflecting an 8.71% increase from ¥25,769,764.03 in the previous year[5]. - The operating profit for the current period was ¥40,366,908.11, compared to ¥34,168,912.27 in the previous period, reflecting an increase of approximately 18.5%[26]. - The net profit for the current period is 34,798,977.44, an increase from 29,828,839.74 in the previous period, representing a growth of approximately 16.6%[27]. - The basic earnings per share increased to 0.33 from 0.28, reflecting a growth of 17.9%[27]. Cash Flow - The company's cash flow from operating activities decreased by 45.52% to ¥12,691,497.99, down from ¥23,295,794.97 in the same period last year[5]. - Cash inflow from operating activities totaled 125,934,658.53, compared to 88,161,991.28 in the previous period, marking an increase of 42.8%[29]. - The net cash flow from operating activities decreased to 12,691,497.99 from 23,295,794.97, a decline of 45.5%[29]. - The net cash flow from investing activities was 178,548,238.57, a significant improvement from -22,411,271.01 in the previous period[29]. - The total cash and cash equivalents at the end of the period amounted to 551,505,762.15, compared to 1,246,675,971.66 at the end of the previous period[31]. - The company received cash from investment recovery totaling 500,854,381.76, indicating strong investment performance[29]. - The cash outflow for purchasing fixed assets and other long-term assets was 23,287,060.01, up from 11,379,182.85 in the previous period[29]. - The company reported a tax refund of 5,628,774.47, an increase from 3,103,370.16 in the previous period[29]. - The company experienced a negative cash flow from financing activities of -474,955.25, an improvement from -9,629,027.59 in the previous period[31]. Assets and Liabilities - Total assets at the end of Q1 2025 were ¥2,386,547,722.91, a 1.57% increase from ¥2,349,619,175.62 at the end of the previous year[5]. - The equity attributable to shareholders increased by 1.64% to ¥2,305,483,690.99 from ¥2,268,268,615.84 at the end of the previous year[5]. - The company's inventory decreased slightly to ¥114,347,242.51 from ¥116,702,724.85, indicating a reduction of about 2%[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,639[13]. - The largest shareholder, Zhu Yong, holds 47.40% of the shares, totaling 51,192,000 shares[13]. - The top ten shareholders hold a combined total of 67,758,225 shares, which represents a significant portion of the company's equity[17]. - The company has a total of 72,515,000 restricted shares, with 13,136,000 shares released during the reporting period[17]. - The company has no preferred shareholders or changes in restricted shares during the reporting period[15]. - The company has not engaged in any financing or securities lending activities among the top ten shareholders[14]. Share Repurchase - The company has repurchased a total of 1,028,148 shares, accounting for 0.95% of the total share capital, with a total transaction amount of approximately 41.99 million RMB[18]. - The maximum transaction price during the share repurchase was 51.50 RMB per share, while the minimum was 33.46 RMB per share[18]. - The company plans to use repurchased shares for equity incentives or employee stock ownership plans[18]. - The company has a clear plan for future share repurchases, aligning with its strategic goals[18]. Investments and Expansion - The company established a wholly-owned subsidiary "Highfine Biotech GmbH" in Germany with a registered capital of €200,000 to enhance its competitiveness and expand its market presence in Europe[19]. - The production capacity at the Anhui Haofan Phase I project of 350 tons commenced operations in August 2022, and a new project with an annual capacity of 1,002 tons received its production license in January 2025[21]. - The company plans to continue enhancing production management and advancing capacity construction despite potential risks related to policy changes and market conditions[21]. Operating Costs - The company experienced a 46.31% rise in operating costs, amounting to ¥82,708,972.55, attributed to increased sales volume[10]. - The total operating costs for the current period were ¥102,006,985.59, up from ¥61,494,588.69 in the previous period, indicating an increase of about 65.8%[26].
昊帆生物(301393) - 2025 Q1 - 季度财报